Paul D. Kemmitt

Discovery of a Potent and Selective EGFR Inhibitor (AZD9291) of Both Sensitizing and T790M Resistance Mutations That Spares the Wild Type Form of the Receptor

M. Raymond V. Finlay, Mark J. Anderton, Susan Ashton et al. · Journal of Medicinal Chemistry · 2014 · 590 citations · Full text

Genetics, Pathology, Clinical Candidate +18

Development of a Novel B-Cell Lymphoma 6 (BCL6) PROTAC To Provide Insight into Small Molecule Targeting of BCL6

William McCoull, Tony Cheung, Erica Anderson et al. · ACS Chemical Biology · 2018 · 133 citations · Full text

Hematological Malignancy, Lymphoid Neoplasia, B-cell Lymphoma 6 +14

Design and optimisation of dendrimer-conjugated Bcl-2/xL inhibitor, AZD0466, with improved therapeutic index for cancer therapy

Claire Patterson, Srividya B. Balachander, Iain Grant et al. · Communications Biology · 2021 · 89 citations · Full text

Structure-Based Design and Pharmacokinetic Optimization of Covalent Allosteric Inhibitors of the Mutant GTPase KRAS^G12C

Jason G. Kettle, Sharan K. Bagal, Sue Bickerton et al. · Journal of Medicinal Chemistry · 2020 · 80 citations · Full text

Discovery of Pyrazolo[1,5-<i>a</i>]pyrimidine B-Cell Lymphoma 6 (BCL6) Binders and Optimization to High Affinity Macrocyclic Inhibitors

William McCoull, Roman Abrams, Erica Anderson et al. · Journal of Medicinal Chemistry · 2017 · 78 citations · Full text